Please assess the completion status of the following clinical trial:

Trial Title: A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~A subject was eligible for inclusion in this study if all of the following criteria applied:~1. Male or non-pregnant female subjects with a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical conditions expected to require daily NSAID therapy for at least 12 months:~   who were~  * 18-49 years of age and had a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years or, who were~  * 50 years of age and older (These subjects did not require a history of a documented, uncomplicated gastric or duodenal ulcer within the past 5 years).~2. Female subjects were eligible for participation in the study if they were of~   * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant);~  * Childbearing potential, had negative pregnancy test at Screening, and at least 1 of the following applied or was agreed to by the subject:~  * Female sterilization or sterilization of male partner; or,~  * Hormonal contraception by oral route, implant, injectable, vaginal ring; or,~  * Any intrauterine device with published data showing that the lowest expected failure rate is less than 1% per year; or,~  * Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or~  * Any other method with published data showing that the lowest expected failure rate is less than 1% per year~3. Each subject was required to be able and willing to provide written informed consent prior to any study procedures being performed.~Exclusion Criteria~A subject was not eligible for inclusion in this study if any 1 or more of the following criteria applied:~1. History of hypersensitivity to esomeprazole or to another PPI~2. History of allergic reaction or intolerance to any NSAID (including aspirin) and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps~3. Participation in any study of an investigational treatment in the 4 weeks before Screening~4. Presence of uncontrolled acute or chronic medical illness, e.g., GI disorder, hypertension, diabetes, thyroid disorder, depression and/or infection that would have endangered a subject if he/she were to participate in the study~5. GI disorder or surgery leading to impaired drug absorption~6. Evidence of uncontrolled or unstable cardio- or cerebrovascular disorder which in the investigator's opinion would have endangered a subject if he/she were to participate in the study~7. Schizophrenia or bipolar disorder~8. Use of any excluded concomitant medication~9. A recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including overuse/abuse of narcotics for management of pain~10. Serious blood coagulation disorder, including use of systemic anticoagulants~11. Positive test result for Helicobacter pylori at Screening~12. Baseline endoscopy showing any gastric or duodenal ulcer at least 3 mm in diameter with depth~13. Screening laboratory value for any of the following tests that was \> 2 times the upper limit of normal: alanine aminotransferase (ALT) and aspartate aminotransferase (AST)~14. Estimated creatinine clearance \< 50 mL/min~15. Other than noted specifically, any screening laboratory value that was clinically significant in the investigator's opinion and would have endangered a subject if the subject were to participate in the study~16. History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PN 400 (VIMOVO) (Type: EXPERIMENTAL): 500 mg delayed release naproxen/20 mg immediate release esomeprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete